Recent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created...
discusses both companies' earnings results , with Eli Lilly seeing strong sales of its GLP-1 drugs Mounjaro and Zepbound. Khemlani also takes a look at some of the other pharmaceutical companies in the GLP-1 space.Another trending story that we are watching here in the health care space G LP one, a key driver of the broader health care space.This earning season, companies like Eli Lily and no, no showing the demand for weight loss treatments does remain strong.
Pfizer, however, has been slowing down its prospects decreasing as it ran into some trouble with its drug, the oral GP one that it is now in clinical trials with it still figuring out the dosing for its one daily and it had a that didn't have good tolerability.Meanwhile, Amgen, moving ahead with its once monthly potentially injectable, that's in phase two and going to be going to phase three trial soon.
After one of the most exciting games in United States men's basketball history, Kevin Durant was awake early in the morning. The late Kobe Bryant, who was Durant's teammate the 2012 London Olympics, used to discuss the Antoniette Costa Reveals She Underwent Brain Surgery: 'There Was a Risk That I Wouldn't Be Able to Sing Again'
Novo Nordisk Anjalee Khemlani Earnings Results Strong Sales
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly stock jumps on GLP-1 sales, end of manufacturing shortageEli Lilly's blowout quarter driven by GLP-1s signals end of manufacturing constraints.
Read more »
Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earningsShares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The...
Read more »
Eli Lilly loses $120B in value over Viking's GLP-1 progressPharmaceutical giant Eli Lilly (LLY) lost approximately $120 billion in market value this week following an announcement from competitor Viking Therapeutics ...
Read more »
Novo Nordisk, Eli Lilly fall on data from Roche's weight-loss pillShares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill...
Read more »
Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billionEli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion
Read more »
Eli Lilly raises annual forecasts as quarterly sales of weight-loss drug cross US$1-billionEli Lilly now expects adjusted profit of $16.10 to $16.60 per share for 2024, compared with its prior forecast of $13.50 to $14
Read more »